C09CA02 - Eprosartan |
Not porphyrinogenic |
NP |
Rationale
Poorly absorbed, not metabolised.
Chemical description
(To be edited, initial data ST OCT 04) Angiotensin II receptor antagonist. Weak inhibitor of CYP 2C9 in vitro. Biovailability only 13 % dependent on poor absorbtion. Excreted in unchanged form.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
© NAPOS 2024